HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Weight Management


The Endocrinology Network® Weight Management clinical resource center is the home of all content related to weight loss and obesity management. Now a full-blown epidemic, the obesity crisis is one of the most prominent and dangerous health crises in the US. This page will provide insight and perspective related to FDA approvals, the latest studies, and guideline updates related to nutrition, obesity, and weight management.

Oral Butyrate Supplementation Could Be Effective in Treating Pediatric Obesity

December 06, 2022

Data from the BAPO trial suggests use of oral butyrate supplementation was associated with a 40% absolute increase in rate of the trial's BMI-based primary outcome at 6 months relative to placebo therapy in a population of pediatric patients with obesity.

How Evolving Safety Has Changed the Outlook on Bariatric, Metabolic Surgery, with Gregory Weiss, MD

December 02, 2022

Gregory Weiss, MD, provides perspective on how improved safety of these procedures has revolutionized the way clinicians view use of bariatric and metabolic surgeries as a method for inducing weight loss in people with overweight and obesity.

Female Sex, Increased BMI Linked to Increased Likelihood of Long COVID

December 01, 2022

An analysis of survey data from more than 1400 adults in the UK provides insight into potential risk factors for developing long COVID symptoms, with results indicating both female sex and increased body mass index as potential risk factors.

Diabetes Dialogue: Obesity Updates, with Lydia Alexander, MD

November 14, 2022

In this episode, our hosts are joined by Lydia Alexander, MD, president-elect of the Obesity Medicine Association, to discuss the updates in the landscape of obesity management as well as a deep dive into the recent American Gastroenterological Association guidelines for pharmacological management and the OMA's annual meeting.

STEP TEENS: Semaglutide 2.4 mg (Wegovy) Weight Loss Benefits Translate to Adolescent Populations

November 02, 2022

Data from the STEP TEENS trial, which assessed the benefits of semaglutide 2.4 mg (Wegovy) in individuals aged 12-18 years with overweight or obesity, indicates use of the GLP-1 receptor agonist was associated with a mean reduction in body weight of 16% during the 68-week trial.

Endocrine Month in Review: October 2022

October 29, 2022

The October 2022 month in review recap includes a pair of studies that paint a grim picture related to the burden of diabetes in the US, a trio of new obesity guidelines/reports from major national and international organizations, and news related to the latest developments in the world of continuous glucose monitoring.

American, International Organizations Debut New Bariatric and Metabolic Surgery Guidelines

October 23, 2022

Published on October 21, the metabolic and bariatric surgery guideline considerations from the American Society of Metabolic and Bariatric Surgery and the International Federation for the Surgery of Obesity and Metabolic Disorders represent the first major updates to guidance since a National Institutes of Health document released in 1991.